Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexmethylphenidate controlled release - Cingulate Therapeutics

X
Drug Profile

Dexmethylphenidate controlled release - Cingulate Therapeutics

Alternative Names: CTX-1301; Dexmethylphenidate HCl

Latest Information Update: 16 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cingulate Therapeutics
  • Developer Bio-Images Drug Delivery; Cingulate Therapeutics
  • Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Dopamine uptake inhibitors; Neurokinin 1 antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder

Most Recent Events

  • 12 Sep 2024 Cingulate Therapeutics commenced its final FDA-required study (Food effect study) for CTx 1301 in attention deficit hyperactivity disorder (ADHD)
  • 16 Aug 2024 Cingulate Therapeutics terminates a phase III trial for Attention-deficit hyperactivity disorder (In children) in USA (PO), due to continuation of the study is not required for NDA submission via the 505(b) pathway (NCT0594594)
  • 15 Aug 2024 Cingulate Therapeutics has patent protection for dexmethylphenidate controlled release in European union and United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top